- Home
- UXIN vs STOK Comparison
UXIN vs STOK Comparison
Compare UXIN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UXIN
- STOK
- Stock Information
- Founded
- UXIN 2011
- STOK 2014
- Country
- UXIN China
- STOK United States
- Employees
- UXIN N/A
- STOK N/A
- Industry
- UXIN Business Services
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- UXIN Consumer Discretionary
- STOK Health Care
- Exchange
- UXIN Nasdaq
- STOK Nasdaq
- Market Cap
- UXIN 744.3M
- STOK 721.4M
- IPO Year
- UXIN 2018
- STOK 2019
- Fundamental
- Price
- UXIN $4.52
- STOK $12.03
- Analyst Decision
- UXIN
- STOK Strong Buy
- Analyst Count
- UXIN 0
- STOK 7
- Target Price
- UXIN N/A
- STOK $21.40
- AVG Volume (30 Days)
- UXIN 194.6K
- STOK 405.8K
- Earning Date
- UXIN 11-26-2024
- STOK 11-05-2024
- Dividend Yield
- UXIN N/A
- STOK N/A
- EPS Growth
- UXIN N/A
- STOK N/A
- EPS
- UXIN N/A
- STOK N/A
- Revenue
- UXIN $204,611,457.00
- STOK $16,742,999.00
- Revenue This Year
- UXIN $26.86
- STOK $91.67
- Revenue Next Year
- UXIN N/A
- STOK $5.45
- P/E Ratio
- UXIN N/A
- STOK N/A
- Revenue Growth
- UXIN N/A
- STOK 81.08
- 52 Week Low
- UXIN $1.41
- STOK $3.77
- 52 Week High
- UXIN $12.10
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- UXIN 50.77
- STOK 39.51
- Support Level
- UXIN $4.18
- STOK $13.39
- Resistance Level
- UXIN $5.00
- STOK $14.72
- Average True Range (ATR)
- UXIN 0.56
- STOK 0.68
- MACD
- UXIN -0.01
- STOK 0.03
- Stochastic Oscillator
- UXIN 54.73
- STOK 7.24
About UXIN Uxin Limited ADS
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.